Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
  • entries
    661
  • comments
    0
  • views
    2,141

About this blog

Drug repurposing enables drug developers to optimize on past efforts and expenditure, thereby, offering a viable life cycle management strategy for marketed products and opportunities to re-evaluate failed / shelved drug development programs

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Drug Repurposing Service Providers Market, 2020-2030.

 

The report features an extensive study of the current market landscape and future opportunities for players offering services for repurposing / repositioning / reprofiling of drug candidates. It features an in-depth analysis, highlighting the capabilities of various service providers engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of companies offering drug repurposing services. 

§  Elaborate profiles of key players that specialize in offering services for the development of repurposed drugs.

§  An analysis of the partnerships that have been established in this domain, in the recent past.

§  An analysis of the initiatives of big biopharma players engaged in this domain.

§  A detailed analysis of more than 1,700 terminated / withdrawn / suspended clinical studies of the drug candidates.

§  A detailed analysis on the cost saving potential of drug repurposing approaches, as compared to the traditional de novo drug development methods.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  • Type of Repurposing Approaches

§  Disease-centric approach

§  Target-centric approach

§  Drug-centric approach

  • Therapeutic Area

§  Same Therapeutic Area

§  Different Therapeutic Area

  • Type of Drug Molecule

§  Biologics 

§  Small Molecule

  • Key Geographical Region 

§  North America

§  Europe

§  Asia-Pacific

 

Key companies covered in the report

§  Auxillis Pharma

§  ChemBio Discovery Solutions

§  Excelra

§  GVK Bio

§  Iris Pharma

§  Lantern Pharma

§  PanXome

§  Pharmacelera

§  Physiogenex

§  Smart Pharma

§  Socium

§  SOM Biotech

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

 

Other Recent Offerings

1.     Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020 - 2030

2.     China Biopharmaceutical Contract Manufacturing Market, 2020-2030

3.     Antibody Contract Manufacturing Market, 2020 - 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

Entries in this blog

With two approved drugs and close to 300 clinical / preclinical product candidates<Roots>

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.   To order this 370+ page report, which features 90+ figures and 110+ tables, please v

With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.   To order this 370+ page report, which features 90+ figures and 110+ tables, please v

With over 280 therapies under evaluation, the stem cell therapy marketRootsAnalysis

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”.  

With over 280 therapies under evaluation, the stem cell therapy market{Roots}

Roots Analysis has done a detailed study on “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”covering key aspects of the industry’s evolution and

With over 280 therapies under evaluation, the stem cell therapy market{Roots:}

Roots Analysis has done a detailed study on “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”covering key aspects of the industry’s evolution and

With over 280 therapies under evaluation, the stem cell therapy market(RootsAnalysis)

With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.   Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical T

With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030\RootsAnalysis

With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.   Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical T

With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030:By RootsAnalysis

Roots Analysis has done a detailed study on “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”covering key aspects of the industry’s evolution and

With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030

With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.   Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical T

With four approved products and many candidate therapies under evaluation<RootsAnalysis>

Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pip

The virtual clinical trial service providers market is projected to grow: By RootsAnalysis:

Roots Analysis has done a detailed study on Virtual Clinical Trial Service Providers Market, 2020-2050, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 280+ page report, which features 180+ figures and 230+ tables, please visit this link   Key Market Insights §  Currently, many companies claim to have advanced technology platforms, which enable them to decentralize the clinical research process, the

Narender

Narender in Roots Analysis

The virtual clinical trial service providers market is projected to grow at an annualized rate{Roots}

Roots Analysis has done a detailed study on Virtual Clinical Trial Service Providers Market, 2020-2050, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 280+ page report, which features 180+ figures and 230+ tables, please visit this link   Key Market Insights §  Currently, many companies claim to have advanced technology platforms, which enable them to decentralize the clinical research process, the

The virtual clinical trial service providers market is estimated to be worth USD 12 billion in 2050(RootsAnalysis)

Conventional clinical trials are fraught with inefficient patient management and data handling practices, which has prompted trial sponsors to implement digital innovation and virtual technologies across different aspects of drug development.   Roots Analysis is pleased to announce the publication of its recent study, titled, “Virtual Clinical Trial Service Providers Market, 2020-2050”   The report features an extensive study of the current landscape of industry players that

The virtual clinical trial service providers market is estimated to be worth USD 12 billion in 2050:By Roots:

Roots Analysis is pleased to announce the publication of its recent study, titled, “Virtual Clinical Trial Service Providers Market, 2020-2050”   The report features an extensive study of the current landscape of industry players that are offering various types of innovative clinical research platforms / solutions to the pharmaceutical and life sciences industries. Amongst other elements, the report features: §  An overview of the current market landscape of companies offering sol

Narender

Narender in Roots Analysis

The targeted protein degradation market is projected to grow at an annualized rate of more than 30%(Roots)

Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 330+ page rep

The targeted protein degradation market is projected to grow at an annualized rate of more than 30% till 2030

Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 330+ page rep

Narender

Narender in Roots Analysis

The targeted protein degradation market is projected to grow at an annualized rate of more than 30% till 2030

Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 330+ page rep

The targeted protein degradation enabling technologies market(Roots)

Roots Analysis has announced the addition of “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings.   Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease causing / associated proteins, using bifunctional small molecule drugs. Presently, the most

The targeted protein degradation enabling technologies market, featuring a healthy pipeline{Roots}

Roots Analysis has done a detailed study on “Targeted Protein Degradation Market, 2021-2030.”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 330+ page report, which features 115+ figures and 180+ tables, please visit this link   Key Market Insights §  Presently, several small molecule protein degraders are being evaluated for the treatment of a wide variety of disease indications; PROTACs is the m

The targeted protein degradation enabling technologies market, featuring a healthy pipeline(RootsAnalysis)

Targeted protein degradation (TPD) is considered to be a transformative approach to selectively eliminate disease-causing proteins; over time, this upcoming class of small molecules has generated significant enthusiasm within the medical community   Roots Analysis is pleased to announce the publication of its recent study, titled, “Targeted Protein Degradation Market, 2021-2030.”   The report features an extensive study of the current market landscape, offering an informed o

The synthetic lethality-based drugs and targets market is projected to grow: By RootsAnalysis:

Roots Analysis has done a detailed study on “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-target

The synthetic lethality-based drugs and targets market is projected to grow at an annualized rate of ~18%, till 2030

Roots Analysis has done a detailed study on “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 485+ page report, which features 195+ figures and 200+ tables, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-m

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030:By Roots:

Roots Analysis is pleased to announce the publication of its recent study, titled, “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.   The  report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030

Roots Analysis is pleased to announce the publication of its recent study, titled, “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.   The  report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilit

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180: By RootsAnalysis:

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html   Key Market Insights §   Eminent representatives from biopharmaceutical companies confirm the rising interest in the concept of subcutaneous drug delivery, highlighting some of the key drivers and upcoming trends in this domain §   More than 100 subcutaneous biologics have been approved
×
  • Create New...